Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALD-103 allo-HSCT outcomes study in boys with cerebral adrenoleukodystrophy
NL-OMON47132Active, not recruiting
- Sponsor
- bluebird bio, Inc.
- Start
- Apr 2015
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of allogeneic hematopoietic stem cell transplantation in cerebral adrenoleukodystrophy (CALD) and adrenoleukodystrophy (ALD) (3 cohorts), sponsored by bluebird bio, Inc. Primary endpoints: Transplant-related mortality through Day 100 and Day 365, Neutrophil engraftment and 11 more. Started Apr 2015; status: active, not recruiting.
02
Drugs
allogeneic hematopoietic stem cell transplantation
03
Conditions
cerebral adrenoleukodystrophy (CALD)adrenoleukodystrophy (ALD)
Beyond the preview
Go deeper on NL-OMON47132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47132.